Price$202.65-3.13 (-1.52%)
01:30 PM07:45 PM
News · 26 weeks110+6%
2025-11-092026-05-03
Mix8090d
- Other38(48%)
- Insider24(30%)
- SEC Filings11(14%)
- Analyst4(5%)
- Earnings2(3%)
- Dividends1(1%)
Latest news
25 items- PRAbbVie to Present at the Bank of America Securities Healthcare ConferenceNORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026. Management will participate in a fireside chat at 1:20 p.m. Central Time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therape
- PRAbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, and durability NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18 abstracts, including real-world evidence and long-term findings for SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) in Crohn's disease and ulcerative colitis. "As a leader in gastroenterology, AbbVie remains focused on advancing
- PRNImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBDNew data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn's disease A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn's disease patients I&I oral therapeutic
- PRSKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative ColitisSKYRIZI® (risankizumab) has been listed in Ontario (ON)1 and Alberta (AB)2 formularies for the treatment of moderately to severely active ulcerative colitis (UC).SKYRIZI® (risankizumab), an IL-23 inhibitor3, received positive reimbursement recommendations for Crohn's disease (CD) and ulcerative colitis (UC).4AbbVie received a letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® for UC in November 2025.5MONTREAL, May 4, 2026 /CNW/ - Today, AbbVie (NYSE:ABBV) has announced two positive updates for Canadians living with UC, including those in Ontario and Alberta.
- PRAbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in QuebecNational competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec.Award provides RIME Therapeutics with a year of laboratory and office space, including access to shared equipment and services at the adMare Innovation Centre in Montreal, as well as mentorship from AbbVie's scientific and business leaders. RIME Therapeutics to impact inflammation and immunology research and innovation. MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV), jointly with adMare BioInnovations, today recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award, a prize designed to help foster innovati
- ANALYSTAbbVie upgraded by BofA Securities with a new price targetBofA Securities upgraded AbbVie from Neutral to Buy and set a new price target of $234.00
- SECAbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie Reports First-Quarter 2026 Financial ResultsReports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $15.002 Billion, an Increase of 12.4 Percent on a Reported Basis or 10.3 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $7.290 Billion, an Increase of 16.4 Percent on a Reported Basis, or 14.3 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.483 Billion; Global Rinvoq Net Revenues Were $2.119 Billion; Global Humira Net Revenu
- PRAbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia AreataSubmission is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of severity of alopecia tool (SALT) score ≤ 20 at week 24, with additional efficacy results observed at week 521-3Upadacitinib is also the first JAK inhibitor to meet the ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 241-3NORTH CHICAGO, Ill., April 28, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia are
- PRRINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitorUpadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP ≤3.2) and ranked secondary endpoint of remission (DAS28-CRP <2.6) at week 121SELECT-SWITCH is the first Phase 3b/4 head-to-head trial comparing TNF inhibitor cycling with switching to upadacitinib in adults with moderate to severe rheumatoid arthritis and inadequate response or intolerance to a TNF inhibitor1The safety profile for upadacitinib was consistent with previously reported studies, with no new safety risks identified in the 12-week period1,2The SELECT-SWITCH study results were recently published in Annals of the Rheumatic Diseases1.MONTREAL, April 28, 2026 /CNW/
- PREvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVieBRANFORD, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2 costimulation, today announced the nomination of a development candidate against a solid tumor target as part of its ongoing partnership with AbbVie (NYSE:ABBV). Achievement of this pre-defined preclinical milestone triggers an $18 million milestone payment to EvolveImmune. The program is being advanced under a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology initiated between EvolveImmune and AbbVie in October 2024. The collaborat
- PRAbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's DiseaseSubmission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa which is already approved for intravenous (IV) inductionNORTH CHICAGO, Ill., April 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD). "Crohn's disease is a chronic inflammatory condition that affects an estimated 1 million Americans, and its impact often reac
- PRAbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for trenibotulinumtoxinE (TrenibotE) related to manufacturing processes; no additional clinical studies are requested As the leader in neurotoxin development and manufacturing, AbbVie is well positioned to address all comments in a timely mannerNORTH CHICAGO, Ill., April 23, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE), a first-in-class botulinum neurotoxin serotype E with a rapid onset of effect and short duration. In
- PRAbbVie Selects North Carolina for New $1.4 Billion Manufacturing CampusMarks AbbVie's largest-ever capital investment in a single campus since its inceptionInvestment demonstrates continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decadeNew 185-acre campus will create 734 jobs to support production of AbbVie's immunology, neuroscience and oncology medicinesConstruction begins in 2026, with completion expected by the end of 2028NORTH CHICAGO, Ill., April 22, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The state-of-the-art campus will
- ANALYSTCanaccord Genuity initiated coverage on AbbVie with a new price targetCanaccord Genuity initiated coverage of AbbVie with a rating of Buy and set a new price target of $262.00
- PRAbbVie and BioLabs Team Up to Support Life Sciences Innovation in CanadaAbbVie announces founding sponsorship of BioLabs University of Toronto.With this announcement, AbbVie expands its world-wide partnership with BioLabs to foster innovation in life sciences.BioLabs University of Toronto launched a new 40,000-square-foot shared/lab/office facility located in MaRS Discovery District to support Canadian life sciences entrepreneurs and enhance biotech research and development. TORONTO, April 20, 2026 /CNW/ - Today, AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced the expansion of its partnership with BioLabs by becoming the founding sponsor of the new BioLabs University of Toronto. The AbbVie and BioLabs collaboratio
- PRErin Lichy Gets Real About Her Natrelle® Breast AugmentationThe entrepreneur and mother of four shares her breast augmentation journey, from consultation to post-op, with Natrelle® breast implants. As a champion of authenticity, Lichy hopes her transparency will help normalize the conversation around breast surgery.IRVINE, Calif., April 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is opening up about her recent breast augmentation with market-leading Natrelle® breast implants in an effort to promote transparency and normalize conversations around aesthetic procedures. As a mom of four, and after years of breastfeeding, Lichy's d
- PRHaisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for PainBEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE:ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds designed to address pain-related indications. These compounds are currently at various development stages in China, ranging from preclinical to Phase 1 clinical development."This collaboration is highly ali
- PRAbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026Results from the Phase 2 IMGN853-0420 trial show an objective response rate of 62.7% and consistent safety findings with mirvetuximab soravtansine-gynx (ELAHERE®) plus carboplatin followed by a continuation of mirvetuximab soravtansine monotherapy in patients with ≥50 % folate receptor alpha (FRα)-expressing, platinum-sensitive ovarian cancer (PSOC).Findings highlight mirvetuximab soravtansine's potential across the ovarian cancer treatment continuum. Data is being presented in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) Annual Meeting. NORTH CHICAGO, Ill., April 12, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that late-breaking results from the
- PRBOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth YearApplications Are Open Now Through April 29 for Entrepreneurs to Apply and Further Unlock Their Potential.Since 2023, the Brand Has Awarded $1.2M to Grant Winners to Boost Their Businesses.This is the Fourth Year BOTOX® Cosmetic is Supporting Entrepreneurs Through Education and Grants to Help Them Grow and Pursue Their Dreams.IRVINE, Calif., April 8, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced that applications are now open for The Confidence Collective: Empowering Women Entrepreneurs, an ongoing initiative from BOTOX® Cosmetic dedicated to uplifting and investing in businessowners. Applications are open now through April 29, 2026.
- PRAllergan Aesthetics Third State-of-the-Art AMI Center Opens in AustinThe Allergan Medical Institute (AMI) Austin location strengthens the national training network with comprehensive, hands-on education.The Orange County and Atlanta AMI centers continue delivering best-in-class, expert-led aesthetics training focused on improving the treatment experience for patients.IRVINE, Calif., April 7, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE:ABBV) company, today announced the opening of the new AMI Austin in Texas. This location marks the third U.S. AMI Training Center opened in the past year and reflects continued investment in aesthetics education.
- SECAbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- INSIDERSEC Form 4 filed by Rapp Edward J4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERSEC Form 4 filed by Alpern Robert J4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERSEC Form 4 filed by Quaggin Susan E4 - AbbVie Inc. (0001551152) (Issuer)
ABBV FAQ
8 questionsWhat does AbbVie Inc. do?
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus...Where does ABBV stock trade?
AbbVie Inc. (ABBV) is listed on NYSE.What sector and industry is ABBV in?
AbbVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbbVie Inc. go public?
AbbVie Inc. (ABBV) completed its IPO in 2012.Does ABBV pay a dividend?
ABBV's most recent ex-dividend date was 2026-04-15 with a cash dividend of $1.73 per share. No future ex-date is on file yet.What are analysts saying about ABBV?
AbbVie Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-04-30.What companies are similar to ABBV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), NVS (Novartis AG), AMGN (Amgen Inc.), ABT (Abbott Laboratories). Compare ABBV side-by-side with any of them on Quantisnow.How can I track ABBV on Quantisnow?
Quantisnow aggregates AbbVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABBV to receive live email and push alerts on every new disclosure.